Pharvaris Trades Flat as Investors Wait for June Data Update
Pharvaris N.V. inched up Friday after the Dutch drugmaker said its main angioedema drug will have clinical data presented at a top allergy and immunology event next month. Shares traded at $30.00 in afternoon Nasdaq action, up around 0.5%, after swinging from $29.58 to $30.34. The SPDR S&P Biotech ETF was up by about 0.5%, but the iShares Nasdaq Biotechnology ETF dipped 0.2%. Pharvaris tracked pretty close to other small-cap biotechs.